Published in Pediatr Nephrol on October 18, 2008
Successful treatment of severe juvenile microscopic polyangiitis with rituximab. Clin Rheumatol (2009) 0.78
Vasculitides associated with IgG antineutrophil cytoplasmic autoantibodies in childhood. Pediatr Nephrol (2009) 0.75
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol (2007) 6.13
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum (2006) 5.68
Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med (2005) 5.17
Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease. J Immunol (1978) 3.78
A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med (1999) 3.74
Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2005) 3.35
Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol (2001) 3.07
Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol (2000) 3.05
Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med (2005) 3.04
From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol (2001) 3.02
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol (2005) 3.00
Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med (2007) 2.97
Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med (1995) 2.89
T cell activation in rheumatoid synovium is B cell dependent. J Immunol (2001) 2.73
Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis (2003) 2.40
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis (2008) 2.33
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum (2007) 2.31
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum (2006) 2.17
Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum (2006) 2.14
BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum (2007) 2.08
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum (2003) 2.02
Long-term follow-up study of periarteritis nodosa. Am J Med (1967) 1.76
Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr (2007) 1.75
Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med (1971) 1.70
Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr (2006) 1.70
B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis (2007) 1.62
Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med (2005) 1.60
Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol (2006) 1.60
B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest (1996) 1.56
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) (2006) 1.53
Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol (2007) 1.44
Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis (2005) 1.33
CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol (2005) 1.26
Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol (2003) 1.22
Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol (2005) 1.22
A new international classification of childhood vasculitis. Pediatr Nephrol (2006) 1.22
Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide. Clin Rheumatol (2007) 1.08
In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthritis Rheum (2002) 1.01
Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) (2008) 1.01
Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford) (2005) 0.95
Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol (2007) 0.94
Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis (2005) 0.93
Murine lupus genetics: lessons learned. Curr Opin Rheumatol (2001) 0.92
B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child (2007) 0.90
Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford) (2007) 0.90
Rituximab in Churg-Strauss syndrome. Ann Rheum Dis (2006) 0.89
A conspicuous role for B cells In Sjögren's syndrome. Clin Rev Allergy Immunol (2007) 0.84
Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr (2007) 0.84
Immunohistochemical identification of infiltrating mononuclear cells in tubulointerstitial nephritis associated with Sjögren's syndrome. Clin Nephrol (1988) 0.84
Treatment of Polyarteritis Nodosa with Cortisone: Results After Three Years: Report to the Medical Research Council by the Collagen Diseases and Hypersensitivity Panel. Br Med J (1960) 0.78
Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol (2006) 0.78
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol (2009) 5.02
Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med (2011) 4.08
Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med (2005) 3.49
Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2007) 2.38
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis (2006) 2.35
Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2012) 2.33
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis (2010) 2.21
Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol (2004) 1.99
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis (2011) 1.88
Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis (2009) 1.86
Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum (2007) 1.83
Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis (2010) 1.81
Membranoproliferative glomerulonephritis. Pediatr Nephrol (2009) 1.80
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) (2009) 1.48
Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken) (2010) 1.45
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis (2014) 1.45
Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract (2005) 1.44
Venous thromboembolism with concurrent pulmonary haemorrhage in systemic vasculitis. Nephrol Dial Transplant (2012) 1.41
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis (2010) 1.38
Isolated large vessel pulmonary vasculitis as a cause of chronic obstruction of the pulmonary arteries. Pulm Circ (2011) 1.31
The future of damage assessment in vasculitis. J Rheumatol (2007) 1.27
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev (2011) 1.27
Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis (2006) 1.25
Diagnosis and management of ANCA associated vasculitis. BMJ (2012) 1.24
A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) (2011) 1.23
Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology (2004) 1.16
Decision-making algorithm for the STARR procedure in obstructed defecation syndrome: position statement of the group of STARR Pioneers. Surg Innov (2008) 1.16
Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis. Curr Opin Rheumatol (2011) 1.12
The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging (2011) 1.12
Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles. J Am Soc Nephrol (2011) 1.11
Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum (2013) 1.04
Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev (2009) 1.03
Assessment of damage in vasculitis: expert ratings of damage. Rheumatology (Oxford) (2009) 1.03
What nephrologists need to know about antiphospholipid syndrome. Nephrol Dial Transplant (2010) 1.02
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther (2013) 0.99
Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis (2011) 0.96
Mortality in Wegener's granulomatosis: a bimodal pattern. Rheumatology (Oxford) (2010) 0.96
Integration of robotic surgery into routine practice and impacts on communication, collaboration, and decision making: a realist process evaluation protocol. Implement Sci (2014) 0.93
The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis. Autoimmun Rev (2012) 0.92
Management of alveolar hemorrhage in lung vasculitides. Semin Respir Crit Care Med (2011) 0.91
Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Ann Rheum Dis (2010) 0.87
Parvovirus B19 microepidemic in renal transplant recipients with thrombotic microangiopathy and allograft vasculitis. Exp Clin Transplant (2008) 0.86
Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant (2010) 0.84
Reviewing the technological challenges associated with the development of a laparoscopic palpation device. Int J Med Robot (2012) 0.84
Diagnosis and treatment of kidney disease. Best Pract Res Clin Rheumatol (2005) 0.83
A novel RASA1 mutation causing capillary malformation-arteriovenous malformation (CM-AVM) presenting during pregnancy. Am J Med Genet A (2013) 0.80
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. J Nephrol (2014) 0.80
Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol (2014) 0.80
Switching of anti-TNF-α agents in Behçet's disease. Clin Exp Rheumatol (2012) 0.78
Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol (2014) 0.78
Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis. J Nephrol (2007) 0.78
Rituximab treatment for vasculitis. Clin J Am Soc Nephrol (2010) 0.78
Structured clinical assessment of the ear, nose and throat in patients with granulomatosis with polyangiitis (Wegener's). Eur Arch Otorhinolaryngol (2012) 0.77
Current modalities in the diagnosis of pulmonary vasculitis. Expert Opin Med Diagn (2012) 0.77
Quality of life after laparoscopic resection rectopexy. Int J Colorectal Dis (2011) 0.76
A disease activity score for ENT involvement in granulomatosis with polyangiitis (Wegener's). Laryngoscope (2013) 0.76
Long-term damage to the ENT system in Wegener's granulomatosis. Eur Arch Otorhinolaryngol (2010) 0.76
Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. Ann Rheum Dis (2007) 0.75
Predictors of outcome in renal vasculitis. Nephrology (Carlton) (2004) 0.75
Reply: To PMID 22614882. Arthritis Rheum (2013) 0.75
New biologics for glomerular disease on the horizon. Nephron Clin Pract (2014) 0.75
The pulmonary vasculitides. Clin Chest Med (2010) 0.75
Newer therapies for vasculitis. Best Pract Res Clin Rheumatol (2009) 0.75
Auto-immune cholangiopathy in a juvenile patient with systemic lupus erythematosus. Acta Paediatr (2012) 0.75
Introduction: Translational Immunology in Kidney Disease. Semin Nephrol (2017) 0.75